AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 20388196 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening for at-risk adolescents by health professionals
Number of subjects: 11000
Study 20388196 — intervention group
Group type: COMPARATOR
Intervention: Minimal intervention (control group)
Number of subjects: 11000
Study 18541129 — intervention group
Group type: EXPERIMENTAL
Intervention: Generic orlistat (Ranbaxy Laboratories) 120 mg, 3 times daily for 10 days
Number of subjects: 18
Study 18541129 — intervention group
Group type: COMPARATOR
Intervention: Innovator orlistat (Xenical, Roche Laboratories) 120 mg, 3 times daily for 10 days
Number of subjects: 18
Study 18541129 — intervention group
Group type: COMPARATOR
Intervention: Baseline (before treatment)
Number of subjects: 18
Study 18541129 — intervention group
Group type: COMPARATOR
Intervention: Comparison of generic to innovator
Number of subjects: 18
Study 15969876 — intervention group
Group type: EXPERIMENTAL
Intervention: FEX 180 mg/PSE 240 mg combination tablet
Number of subjects: 0
Study 15969876 — intervention group
Group type: COMPARATOR
Intervention: FEX 180 mg immediate-release tablet and PSE 240 mg extended-release tablet (control)
Number of subjects: 0
Study 14662201 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefpodoxime proxetil (100 mg twice a day, 6 days a month for 6 months)
Number of subjects: 180
Study 14662201 — intervention group
Group type: COMPARATOR
Intervention: Placebo (100 mg twice a day, 6 days a month for 6 months)
Number of subjects: 180
Study 10319782 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropivacaine 0.5% (R0.5 group)
Number of subjects: 56
Study 10319782 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropivacaine 0.25% (R0.25 group)
Number of subjects: 56
Study 10319782 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine 0.25% (B0.25 group)
Number of subjects: 56
Study 10319782 — intervention group
Group type: COMPARATOR
Intervention: All groups (R0.5, R0.25, B0.25)
Number of subjects: 56
Study 8952866 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin 40 mg/day for one month
Number of subjects: 20
Study 8952866 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvastatin (exact dosage not specified) for one month
Number of subjects: 20
Study 8952866 — intervention group
Group type: COMPARATOR
Intervention: Control group (normocholesterolemic subjects)
Number of subjects: 20
Study 31493123 — intervention group
Group type: EXPERIMENTAL
Intervention: Catheter ablation
Number of subjects: 0
Study 31493123 — intervention group
Group type: COMPARATOR
Intervention: Drug therapy
Number of subjects: 0
Study 29666135 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard chemotherapy followed by radical radiotherapy (RRT) and stereotactic ablative radiotherapy (SABR) to the primary tumour and SABR/stereotactic radiosurgery (SRS) to all other metastatic sites
Number of subjects: 340
Study 29666135 — intervention group
Group type: COMPARATOR
Intervention: Standard platinum-doublet chemotherapy only
Number of subjects: 340
Study 29666135 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard chemotherapy followed by RRT/SABR
Number of subjects: 340
Study 27404028 — intervention group
Group type: EXPERIMENTAL
Intervention: Conjugated estrogens/bazedoxifene (two doses)
Number of subjects: 318
Study 24463231 — intervention group
Group type: EXPERIMENTAL
Intervention: Lokomat robotic training
Number of subjects: 22
Study 24463231 — intervention group
Group type: COMPARATOR
Intervention: Conventional home exercise
Number of subjects: 22
Study 22435765 — intervention group
Group type: EXPERIMENTAL
Intervention: Five-step implementation process for an acute myocardial infarction clinical pathway (CPW)
Number of subjects: 108
Study 22435765 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 108
Study 20167994 — intervention group
Group type: EXPERIMENTAL
Intervention: Triomune 40 (GT) - quartered tablet dosing (8-<12 kg)
Number of subjects: 18
Study 20167994 — intervention group
Group type: COMPARATOR
Intervention: Generic liquid (GL)
Number of subjects: 18
Study 20167994 — intervention group
Group type: COMPARATOR
Intervention: Trade liquid (TL)
Number of subjects: 18
Study 20167994 — intervention group
Group type: EXPERIMENTAL
Intervention: Triomune 40 (GT) - one-half and three-quarter tablet dosing
Number of subjects: 18
Study 20167994 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison with Western paediatric cohorts
Number of subjects: 18
Study 17379046 — intervention group
Group type: EXPERIMENTAL
Intervention: Controlled-release (CR) tramadol 200 mg every morning plus placebo immediate-release (IR) tramadol 50 mg every 4 to 6 hours PRN rescue
Number of subjects: 122
Study 17379046 — intervention group
Group type: EXPERIMENTAL
Intervention: Controlled-release (CR) tramadol 400 mg every morning plus placebo immediate-release (IR) tramadol 100 mg every 4 to 6 hours PRN rescue
Number of subjects: 122
Study 17379046 — intervention group
Group type: EXPERIMENTAL
Intervention: Controlled-release (CR) tramadol
Number of subjects: 122
Study 17379046 — intervention group
Group type: COMPARATOR
Intervention: Immediate-release (IR) tramadol
Number of subjects: 122
Study 17379046 — intervention group
Group type: EXPERIMENTAL
Intervention: Biweekly VAS pain intensity questionnaire
Number of subjects: 122
Study 17379046 — intervention group
Group type: EXPERIMENTAL
Intervention: Pain and Disability Index (PDI)
Number of subjects: 122
Study 17379046 — intervention group
Group type: EXPERIMENTAL
Intervention: Pain and Sleep Questionnaire
Number of subjects: 122
Study 16282562 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise training (walking and weight lifting 3 days/week for 18 months)
Number of subjects: 214
Study 12081830 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoflavone-rich soy protein isolate (SPI+; n = 24)
Number of subjects: 69
Study 12081830 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoflavone-poor soy protein isolate (SPI-; n = 24)
Number of subjects: 69
Study 12081830 — intervention group
Group type: COMPARATOR
Intervention: Whey protein (control; n = 21)
Number of subjects: 69
Study 12081830 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (SPI+ and SPI- compared to control)
Number of subjects: 69
Study 12081830 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 69
Study 9858441 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise therapy from a physiotherapist in primary care
Number of subjects: 201
Study 9858441 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard treatment from general practitioner)
Number of subjects: 201
Study 7832131 — intervention group
Group type: EXPERIMENTAL
Intervention: Epinephrine infusion (0.39 +/- 0.19 nmol/kg/min)
Number of subjects: 8
Study 7832131 — intervention group
Group type: COMPARATOR
Intervention: Maximal epinephrine dose in control group
Number of subjects: 8
Study 2226729 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose cytosine arabinoside (HD Ara-C) with mitoxantrone (MTX)
Number of subjects: 52
Study 2226729 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose cytosine arabinoside (HD Ara-C) with m-amsacrine (AMSA)
Number of subjects: 52
Study 2226729 — intervention group
Group type: COMPARATOR
Intervention: m-amsacrine (AMSA)
Number of subjects: 52
Study 2226729 — intervention group
Group type: COMPARATOR
Intervention: mitoxantrone (MTX)
Number of subjects: 52
Study 349428 — intervention group
Group type: EXPERIMENTAL
Intervention: Pimozide (Orap)
Number of subjects: 18
Study 349428 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 31432332 — intervention group
Group type: EXPERIMENTAL
Intervention: Gluteal turnover flap (GT-flap) for perineal wound closure after APR
Number of subjects: 10
Study 27742102 — intervention group
Group type: EXPERIMENTAL
Intervention: MyFitnessPal app
Number of subjects: 30
Study 27742102 — intervention group
Group type: COMPARATOR
Intervention: Paper tallying of estimated sodium intake
Number of subjects: 30
Study 26504068 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness workshops (dietetic and psychological approaches)
Number of subjects: 53
Study 26504068 — intervention group
Group type: COMPARATOR
Intervention: Usual practice (control group)
Number of subjects: 53
Study 23644930 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mg/month IV ibandronate
Number of subjects: 1265
Study 23644930 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg/month IV ibandronate
Number of subjects: 1265
Study 23644930 — intervention group
Group type: COMPARATOR
Intervention: 2.5 mg/day oral risedronate
Number of subjects: 1265
Study 21269298 — intervention group
Group type: EXPERIMENTAL
Intervention: Frovatriptan (5.0 mg)
Number of subjects: 74
Study 21269298 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 74
Study 19705288 — intervention group
Group type: EXPERIMENTAL
Intervention: HPV 16 and 18 vaccination
Number of subjects: 1233
Study 16941972 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture at Dazhui (GV 14)
Number of subjects: 86
Study 16941972 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular injection of Antongding Injectio
Number of subjects: 86
Study 15597291 — intervention group
Group type: EXPERIMENTAL
Intervention: Symptoms reported by LTR with rejection (grade >or= A2)
Number of subjects: 0
Study 15597291 — intervention group
Group type: EXPERIMENTAL
Intervention: Symptoms reported by LTR with clinically significant acute rejection (grade >or= A2)
Number of subjects: 0
Study 15597291 — intervention group
Group type: EXPERIMENTAL
Intervention: Symptoms (respiratory, general, or activities of daily living [ADL])
Number of subjects: 0
Study 10786064 — intervention group
Group type: EXPERIMENTAL
Intervention: St. John's Wort (Hypericum perforatum)
Number of subjects: 0
Study 10786064 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 9183333 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjusted-dose warfarin
Number of subjects: 846
Study 9183333 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy (low fixed dose warfarin plus aspirin)
Number of subjects: 846
Study 9183333 — intervention group
Group type: COMPARATOR
Intervention: Aspirin alone
Number of subjects: 846
Study 8222099 — intervention group
Group type: EXPERIMENTAL
Intervention: CGP 39 393
Number of subjects: 113
Study 8222099 — intervention group
Group type: COMPARATOR
Intervention: Heparin
Number of subjects: 113
Study 3759224 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem (180‐270 mg/day)
Number of subjects: 40
Study 3759224 — intervention group
Group type: COMPARATOR
Intervention: Nifedipine (40‐60 mg/day)
Number of subjects: 40
Study 3759224 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem
Number of subjects: 40
Study 3759224 — intervention group
Group type: COMPARATOR
Intervention: Nifedipine
Number of subjects: 40
Study 29020866 — intervention group
Group type: EXPERIMENTAL
Intervention: Epoetin alfa (EPO)
Number of subjects: 606
Study 29020866 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 606
Study 26598037 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine
Number of subjects: 65
Study 26598037 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 65
Study 26598037 — intervention group
Group type: EXPERIMENTAL
Intervention: No preference
Number of subjects: 65
Study 25165158 — intervention group
Group type: EXPERIMENTAL
Intervention: Bibliographical support (literature research)
Number of subjects: 201
Study 23845696 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisolone
Number of subjects: 352
Study 23845696 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 352
Study 20710089 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 19123765 — intervention group
Group type: EXPERIMENTAL
Intervention: Deliberate self-harm (DSH) group
Number of subjects: 500
Study 19123765 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 500
Study 15644657 — intervention group
Group type: EXPERIMENTAL
Intervention: Closed-tracheal suction system
Number of subjects: 443
Study 15644657 — intervention group
Group type: COMPARATOR
Intervention: Open tracheal suction system
Number of subjects: 443
Study 12169860 — intervention group
Group type: EXPERIMENTAL
Intervention: Juice supplemented with Lactobacillus rhamnosus and Propionibacterium freudenreichii
Number of subjects: 28
Study 12169860 — intervention group
Group type: COMPARATOR
Intervention: Juice (control group)
Number of subjects: 28
Study 12169860 — intervention group
Group type: EXPERIMENTAL
Intervention: Juice supplemented with Lactobacillus reuteri
Number of subjects: 28
Study 12179668 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcutaneous electrical nerve stimulation (TENS)
Number of subjects: 68
Study 12179668 — intervention group
Group type: COMPARATOR
Intervention: Control (2% lidocaine)
Number of subjects: 68
Study 7781368 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg of metoclopramide administered 10 min before tube insertion
Number of subjects: 105
Study 7781368 — intervention group
Group type: COMPARATOR
Intervention: No medication (control)
Number of subjects: 105
Study 2107239 — intervention group
Group type: EXPERIMENTAL
Intervention: Prehospital treatment with recombinant tissue‐type plasminogen activator (rt‐PA) in the mobile intensive care unit (group A)
Number of subjects: 118
Study 2107239 — intervention group
Group type: COMPARATOR
Intervention: Hospital treatment (group B)
Number of subjects: 118
Study 2107239 — intervention group
Group type: EXPERIMENTAL
Intervention: Prehospital treatment with rt‐PA (group A)
Number of subjects: 118
Study 7360486 — intervention group
Group type: EXPERIMENTAL
Intervention: Synchronized schedule of VP-16 and adriamycin
Number of subjects: 0
Study 7360486 — intervention group
Group type: COMPARATOR
Intervention: Standard schedule of VP-16 and adriamycin
Number of subjects: 0
Study 31941538 — intervention group
Group type: EXPERIMENTAL
Intervention: Care by a PDNS (who works according to a recent guideline on PDNS care)
Number of subjects: 240
Study 31941538 — intervention group
Group type: COMPARATOR
Intervention: Usual care (without PDNS)
Number of subjects: 240
Study 30719706 — intervention group
Group type: EXPERIMENTAL
Intervention: Arm A (gender-neutral HPV16/18 vaccination)
Number of subjects: 61935
Study 30719706 — intervention group
Group type: COMPARATOR
Intervention: Arm C (gender-neutral HBV vaccination)
Number of subjects: 61935
Study 30719706 — intervention group
Group type: EXPERIMENTAL
Intervention: Arm B (girls-only HPV16/18 vaccination and HBV vaccination of boys)
Number of subjects: 61935
Study 30719706 — intervention group
Group type: COMPARATOR
Intervention: Non-vaccinated group
Number of subjects: 61935
Study 30923964 — intervention group
Group type: EXPERIMENTAL
Intervention: Customized cutting block (CCB)
Number of subjects: 86
Study 30923964 — intervention group
Group type: COMPARATOR
Intervention: Conventional cutting instrument (CCI)
Number of subjects: 86
Study 28462794 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional Electrical Stimulation (FES) applied to wrist and finger extensors
Number of subjects: 30
Study 28462794 — intervention group
Group type: COMPARATOR
Intervention: Control group (no FES)
Number of subjects: 30
Study 25609935 — intervention group
Group type: EXPERIMENTAL
Intervention: Strength Training (ST)
Number of subjects: 22
Study 25609935 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic Training (AT)
Number of subjects: 22
Study 25609935 — intervention group
Group type: COMPARATOR
Intervention: Physiotherapy (Control)
Number of subjects: 22
Study 25609935 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (ST, AT, Physiotherapy)
Number of subjects: 22
Study 23291425 — intervention group
Group type: EXPERIMENTAL
Intervention: NeuroFlo therapy
Number of subjects: 515
Study 23291425 — intervention group
Group type: COMPARATOR
Intervention: Standard medical therapy
Number of subjects: 515
Study 21571448 — intervention group
Group type: EXPERIMENTAL
Intervention: Abrupt cessation (n=472)
Number of subjects: 472
Study 21571448 — intervention group
Group type: EXPERIMENTAL
Intervention: Gradual cessation (n=502)
Number of subjects: 472
Study 21571448 — intervention group
Group type: COMPARATOR
Intervention: No preference, randomized to abrupt (n=2456)
Number of subjects: 472
Study 21571448 — intervention group
Group type: COMPARATOR
Intervention: No preference, randomized to gradual (n=2456)
Number of subjects: 472
Study 18053689 — intervention group
Group type: EXPERIMENTAL
Intervention: Haloperidol
Number of subjects: 164
Study 18053689 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone
Number of subjects: 164
Study 18053689 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 164
Study 16830143 — intervention group
Group type: EXPERIMENTAL
Intervention: Zoledronic acid 4 mg intravenously every 3 months for 12 months
Number of subjects: 18
Study 16830143 — intervention group
Group type: COMPARATOR
Intervention: Control group (10 thalassemic osteoporotic patients with serial BMDs)
Number of subjects: 18
Study 16830143 — intervention group
Group type: EXPERIMENTAL
Intervention: Zoledronic acid treatment
Number of subjects: 18
Study 12957974 — intervention group
Group type: EXPERIMENTAL
Intervention: Methohexital
Number of subjects: 103
Study 12957974 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 103
Study 12957974 — intervention group
Group type: COMPARATOR
Intervention: Control (none)
Number of subjects: 103
Study 11056759 — intervention group
Group type: COMPARATOR
Intervention: Systemic Mediator Associated Response Test (SMART) baseline models
Number of subjects: 303
Study 11056759 — intervention group
Group type: COMPARATOR
Intervention: Systemic Mediator Associated Response Test (SMART) baseline plus serial data models
Number of subjects: 303
Study 11056759 — intervention group
Group type: COMPARATOR
Intervention: SMART predictions of physiologic, respiratory, metabolic, hepatic, renal, and hematologic function indicators
Number of subjects: 303
Study 11056759 — intervention group
Group type: COMPARATOR
Intervention: SMART multivariate models
Number of subjects: 303
Study 11056759 — intervention group
Group type: COMPARATOR
Intervention: SMART predictions for 28-day survival
Number of subjects: 303
Study 9058681 — intervention group
Group type: EXPERIMENTAL
Intervention: Flunisolide 500 microg qd in the morning
Number of subjects: 366
Study 9058681 — intervention group
Group type: EXPERIMENTAL
Intervention: Flunisolide 1000 microg qd in the morning
Number of subjects: 366
Study 9058681 — intervention group
Group type: EXPERIMENTAL
Intervention: Flunisolide 1000 microg qd in the evening
Number of subjects: 366
Study 9058681 — intervention group
Group type: EXPERIMENTAL
Intervention: Flunisolide 500 microg bid
Number of subjects: 366
Study 8138867 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment instituted at bedtime
Number of subjects: 6
Study 3763918 — intervention group
Group type: EXPERIMENTAL
Intervention: Ioxaglate sodium meglumine
Number of subjects: 0
Study 3763918 — intervention group
Group type: COMPARATOR
Intervention: Iopamidol
Number of subjects: 0
Study 29127813 — intervention group
Group type: EXPERIMENTAL
Intervention: Culturally Sensitive Collaborative Treatment (CSCT)
Number of subjects: 280
Study 29127813 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 280
Study 26802916 — intervention group
Group type: EXPERIMENTAL
Intervention: Medication therapy management (MTM) intervention targeting FRIDs
Number of subjects: 80
Study 26802916 — intervention group
Group type: COMPARATOR
Intervention: Control group (no MTM intervention)
Number of subjects: 80
Study 25366678 — intervention group
Group type: EXPERIMENTAL
Intervention: Bladder-preserving combined-modality therapy (CMT)
Number of subjects: 468
Study 21858593 — intervention group
Group type: EXPERIMENTAL
Intervention: Suction drains (DN group, n=15)
Number of subjects: 43
Study 21858593 — intervention group
Group type: EXPERIMENTAL
Intervention: Quilting sutures (QS group, n=13)
Number of subjects: 43
Study 21858593 — intervention group
Group type: COMPARATOR
Intervention: Fibrin sealant (FS group, n=15)
Number of subjects: 43
Study 20349201 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacological treatment (specifics not provided)
Number of subjects: 0
Study 20349201 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 20349201 — intervention group
Group type: COMPARATOR
Intervention: No pharmacological treatment
Number of subjects: 0
Study 20349201 — intervention group
Group type: EXPERIMENTAL
Intervention: Randomized controlled trials (RCTs)
Number of subjects: 0
Study 20349201 — intervention group
Group type: EXPERIMENTAL
Intervention: Recent guidelines from various societies
Number of subjects: 0
Study 19167586 — intervention group
Group type: EXPERIMENTAL
Intervention: Tizanidine 6-mg capsule administered intact
Number of subjects: 28
Study 19167586 — intervention group
Group type: COMPARATOR
Intervention: Tizanidine capsule contents sprinkled in applesauce
Number of subjects: 28
Study 15924530 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxibustion (stimulation with heat from a stick of Artemisia vulgaris) at the BL 67 acupuncture point for one or two weeks
Number of subjects: 123
Study 15924530 — intervention group
Group type: COMPARATOR
Intervention: Control (observation)
Number of subjects: 123
Study 13129466 — intervention group
Group type: EXPERIMENTAL
Intervention: High-MUFA diet (33 g dietary SFA/100 g total fatty acids substituted with MUFA)
Number of subjects: 51
Study 13129466 — intervention group
Group type: COMPARATOR
Intervention: Moderate-MUFA diet (16 g dietary SFA/100 g total fatty acids substituted with MUFA)
Number of subjects: 51
Study 13129466 — intervention group
Group type: EXPERIMENTAL
Intervention: High-MUFA diet
Number of subjects: 51
Study 13129466 — intervention group
Group type: COMPARATOR
Intervention: Moderate-MUFA diet
Number of subjects: 51
Study 10533795 — intervention group
Group type: EXPERIMENTAL
Intervention: UDCA (600 mg/day)
Number of subjects: 45
Study 10533795 — intervention group
Group type: COMPARATOR
Intervention: No therapy (Control)
Number of subjects: 45
Study 8693441 — intervention group
Group type: EXPERIMENTAL
Intervention: Threshold loading device
Number of subjects: 18
Study 2592983 — intervention group
Group type: COMPARATOR
Intervention: Lateral tilting of the body axis (0 degrees control position to 4, 8, 12, 16, 20 degrees test positions)
Number of subjects: 12
Study 2592983 — intervention group
Group type: EXPERIMENTAL
Intervention: Lateral tilting of the body axis (various degrees)
Number of subjects: 12
Study 1246775 — intervention group
Group type: EXPERIMENTAL
Intervention: Resection via perineal urethrostomy (Group B)
Number of subjects: 42
Study 1246775 — intervention group
Group type: COMPARATOR
Intervention: Resection via the entire urethra (Group C)
Number of subjects: 42
Study 31746962 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetically predicted increase in non-HDL-C levels by 1 SD (38 mg/dL)
Number of subjects: 12460